Key result
Secondary PH in HFrEF linked to greater disease severity, higher mortality, and increased hospitalizations.
Why the study?
Secondary PH is a prevalent complication of HFrEF linked to worsened clinical outcomes and decreased responsiveness to therapeutic interventions.
Does secondary pulmonary hypertension influence treatment response and clinical outcomes in patients with HFrEF?
Systematic Review (n=2,930)
Does secondary pulmonary hypertension influence treatment response and clinical outcomes in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
Secondary pulmonary hypertension in HFrEF worsens prognosis and treatment response, highlighting the need for personalized therapeutic strategies targeting both hemodynamic and structural aspects.
Introduction: secondary pulmonary hypertension (PH) is a prevalent complication of heart failure with reduced ejection fraction (HFrEF). This condition is linked to worsened clinical outcomes and decreased responsiveness to therapeutic interventions and leads to poor prognosis of the disease. Methods: the approach used was meta-analysis which was aimed to assess the influence of secondary PH on treatment response in HFrEF. The study included 5 relevant studies that assessed various characteristics of secondary PH in HFrEF patients. Results: te findings indicate that secondary pulmonary hypertension is associated with greater disease severity, higher mortality rates, and increased frequency of hospitalizations. The severity of PH, ventricular function, pulmonary vascular resistance and remodeling, and the interplay between left and right heart dysfunction were identified as important factors affecting treatment response. Conclusion: the study highlighted the need for personalized treatment approaches that target both the hemodynamic and structural aspects of secondary PH in HFrEF. Further research is recommended to develop precise treatment strategies and explore new pharmacological options. Additionally, longitudinal studies are recommended to understand the progression of PH in HFrEF and its clinical implications. The meta-analysis provided valuable insights into the impact of secondary PH on treatment response in HFrEF and emphasized the importance of tailored approaches for optimal patient outcomes
No takes yet. Share an insight, caveat, or question.
Clavijo et al. (2024) conducted a systematic review in Heart failure with reduced ejection fraction (HFrEF) and secondary pulmonary hypertension (n=2,930). Secondary pulmonary hypertension (observational exposure) vs. HFrEF without secondary pulmonary hypertension was evaluated on Treatment response, mortality, and hospitalization. Secondary pulmonary hypertension in patients with heart failure with reduced ejection fraction is associated with greater disease severity, higher mortality rates, and increased hospitalizations.
Synapse has enriched 10 related papers. Consider them for comparative context: